We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much You'd Have If You Invested $1000 in Quidel a Decade Ago
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.
What if you'd invested in Quidel (QDEL - Free Report) ten years ago? It may not have been easy to hold on to QDEL for all that time, but if you did, how much would your investment be worth today?
Quidel's Business In-Depth
With that in mind, let's take a look at Quidel's main business drivers.
San Diego, CA-based Quidel Corporation is a key player in the development, manufacturing and marketing of rapid diagnostic testing solutions. These solutions are separated into four product categories. The company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent-care clinics, leading universities, retail clinics, pharmacies and wellness screening centers. Quidel operates in one business segment that develops, manufactures and markets its four product categories.
Product Categories
Rapid Immunoassay (70.5% of aggregate revenues in FY 2021, up 4.6% from FY 2020): This category includes the Sofia (launched in 2011) and Sofia 2 Analyzers (launched in 2017), QuickVue, InflammaDry and AdenoPlus. Sofia is the brand name for Quidel’s fluorescent immunoassay (FIA) systems. In 2021, Quidel got an amended Emergency Use Authorization (EUA) from the FDA allowing it to market Sofia Q. QuickVue is the brand name for Quidel’s rapid, visually-read, lateral-flow immunoassay products.
Cardiometabolic Immunoassay (15.1%, up 5.3%): This category includes the Triage MeterPro, a portable testing platform that runs a comprehensive menu of tests, enabling physicians to promote improved health outcomes via the rapid diagnosis of critical diseases and health conditions, as well as the detection of certain drugs of abuse. Triage cardiovascular rapid tests include immunoassays for B-type Natriuretic Peptide (BNP), creatine kinase-MB (CK-MB), among others.
Molecular Diagnostic Solutions (11.8%, down 10.1%): This category includes the Lyra, Solana and Savanna systems. Lyra Molecular Real-Time Polymerase Chain Reaction (PCR) assays provide important benefits to the customer.
Specialized Diagnostic Solutions (2.6%, down 12%): This category includes Virology and Specialty Products. Virology product category includes the FDA-cleared bioassay, Thyretain. Under Specialty Products, Quidel provides a variety of biomarkers for bone health and produces both clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation are available.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Quidel, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in April 2012 would be worth $6,335.71, or a gain of 533.57%, as of April 6, 2022, according to our calculations. This return excludes dividends but includes price appreciation.
The S&P 500 rose 223.67% and the price of gold increased 13.22% over the same time frame in comparison.
Analysts are forecasting more upside for QDEL too.
Quidel’s strong Specialized Diagnostic Solutions revenues and strong product sales in fourth-quarter 2021 are impressive. A solid Diagnostics suite and In Vitro Diagnostics (IVD) products’ potential are promising. Product launches by Quidel raise our optimism. A strong balance sheet is an added plus. Quidel’s fourth-quarter results were better than expected. Yet, dismal year-over-year top- and bottom-line results and lower revenues across majority of its product groups are concerning. Contraction of both margins does not bode well. The company not providing any outlook raises apprehensions. Quidel’s operation in a stiff competitive space and its overdependence on diagnostic tests are worrying. Uncertainties from third-party reimbursement policies persists. Over the past six months, Quidel has underperformed its industry.
The stock has jumped 17.68% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 2 higher, for fiscal 2022; the consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Much You'd Have If You Invested $1000 in Quidel a Decade Ago
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
Another thing that can drive investing is the fear of missing out, or FOMO. This particularly applies to tech giants and popular consumer-facing stocks.
What if you'd invested in Quidel (QDEL - Free Report) ten years ago? It may not have been easy to hold on to QDEL for all that time, but if you did, how much would your investment be worth today?
Quidel's Business In-Depth
With that in mind, let's take a look at Quidel's main business drivers.
San Diego, CA-based Quidel Corporation is a key player in the development, manufacturing and marketing of rapid diagnostic testing solutions. These solutions are separated into four product categories. The company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent-care clinics, leading universities, retail clinics, pharmacies and wellness screening centers. Quidel operates in one business segment that develops, manufactures and markets its four product categories.
Product Categories
Rapid Immunoassay (70.5% of aggregate revenues in FY 2021, up 4.6% from FY 2020): This category includes the Sofia (launched in 2011) and Sofia 2 Analyzers (launched in 2017), QuickVue, InflammaDry and AdenoPlus. Sofia is the brand name for Quidel’s fluorescent immunoassay (FIA) systems. In 2021, Quidel got an amended Emergency Use Authorization (EUA) from the FDA allowing it to market Sofia Q. QuickVue is the brand name for Quidel’s rapid, visually-read, lateral-flow immunoassay products.
Cardiometabolic Immunoassay (15.1%, up 5.3%): This category includes the Triage MeterPro, a portable testing platform that runs a comprehensive menu of tests, enabling physicians to promote improved health outcomes via the rapid diagnosis of critical diseases and health conditions, as well as the detection of certain drugs of abuse. Triage cardiovascular rapid tests include immunoassays for B-type Natriuretic Peptide (BNP), creatine kinase-MB (CK-MB), among others.
Molecular Diagnostic Solutions (11.8%, down 10.1%): This category includes the Lyra, Solana and Savanna systems. Lyra Molecular Real-Time Polymerase Chain Reaction (PCR) assays provide important benefits to the customer.
Specialized Diagnostic Solutions (2.6%, down 12%): This category includes Virology and Specialty Products. Virology product category includes the FDA-cleared bioassay, Thyretain. Under Specialty Products, Quidel provides a variety of biomarkers for bone health and produces both clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation are available.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Quidel, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in April 2012 would be worth $6,335.71, or a gain of 533.57%, as of April 6, 2022, according to our calculations. This return excludes dividends but includes price appreciation.
The S&P 500 rose 223.67% and the price of gold increased 13.22% over the same time frame in comparison.
Analysts are forecasting more upside for QDEL too.
Quidel’s strong Specialized Diagnostic Solutions revenues and strong product sales in fourth-quarter 2021 are impressive. A solid Diagnostics suite and In Vitro Diagnostics (IVD) products’ potential are promising. Product launches by Quidel raise our optimism. A strong balance sheet is an added plus. Quidel’s fourth-quarter results were better than expected. Yet, dismal year-over-year top- and bottom-line results and lower revenues across majority of its product groups are concerning. Contraction of both margins does not bode well. The company not providing any outlook raises apprehensions. Quidel’s operation in a stiff competitive space and its overdependence on diagnostic tests are worrying. Uncertainties from third-party reimbursement policies persists. Over the past six months, Quidel has underperformed its industry.
The stock has jumped 17.68% over the past four weeks. Additionally, no earnings estimate has gone lower in the past two months, compared to 2 higher, for fiscal 2022; the consensus estimate has moved up as well.